Johnson & Johnson Net Worth 2010-2024 | JNJ

Interactive chart of historical net worth (market cap) for Johnson & Johnson (JNJ) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Johnson & Johnson net worth as of July 26, 2024 is $384.2B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $384.202B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $780.463B 112.80
Novo Nordisk (NVO) Denmark $573.776B 44.09
AbbVie (ABBV) United States $321.688B 17.02
Merck (MRK) United States $318.754B 57.99
AstraZeneca (AZN) United Kingdom $243.454B 21.69
Novartis AG (NVS) Switzerland $224.697B 15.61
Pfizer (PFE) United States $171.018B 21.25
Sanofi (SNY) $134.488B 12.73
Innoviva (INVA) United States $1.136B 7.98